A trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral antidiabetic drugs
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 28 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2017 Planned End Date changed from 9 Oct 2018 to 10 Oct 2018.
- 19 May 2017 Planned End Date changed from 10 Oct 2018 to 9 Oct 2018.